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Epigenetic and genetic analysis of p16 in dermal fibroblasts an indicator of renal morbidity, but is also associated with
from type 1 diabetic patients with nephropathy. a dramatically increased risk of premature cardiovascular
Background. Several studies have shown that cultured skin disease and increased mortality [3]. Approximately 30%fibroblasts from patients with diabetic nephropathy (DN) ex-
to 40% of patients with type 1 diabetes develop nephrop-hibit a hyperplastic growth phenotype. Increased DNA synthe-
athy, with the incidence reaching a peak during the sec-sis in cells from patients with DN may ultimately involve alter-
ations in cell cycle regulatory proteins. p16 protein is a member ond decade of diabetes and sharply declining thereafter
of INK4 family of cyclin-dependent kinase inhibitors, which [4, 5]. This pattern suggests that only a subset of patients
plays an important role in cell cycle regulation. In this study, with type 1 diabetes is susceptible to DN, and the delete-we examined the correlation between p16 protein expression
rious effects of hyperglycemia, even though necessary,in cultured dermal fibroblasts from type 1 diabetic patients and
are not sufficient to cause kidney disease in diabetic pa-the presence of DN.
Method. Western blot analysis was performed to compare tients. Several lines of evidence suggest genetic suscepti-
p16 protein expression in skin fibroblasts from patients with bility to DN [6–10]. Familial clustering of nephropathy in
DN as compared to control subjects, diabetic patients without
diabetic patients has been demonstrated [6, 7]. A diabeticDN, and nondiabetic patients with nephropathy. Transcrip-
sibling of a person with type 1 diabetes and nephropathytional regulation of the p16 gene was assessed using competitive
reverse transcription-polymerase chain reaction (RT-PCR). has a 72% cumulative risk of developing renal disease,
Methylation status of the promoter region of p16 was examined whereas a diabetic sibling of a person with type 1 diabe-
using methylation-specific PCR, and we used single-stranded tes, but without nephropathy, only has a 25% risk [7].
conformational polymorphism (SSCP)-PCR to assess p16 sin-
To unravel the genetic basis of DN, investigators havegle-nucleotide polymorphism.
described various cellular phenotype and genotype alter-Results. Cells from diabetic patients with DN had nondetect-
able to significantly lower protein expression of p16. Similarly, ations in patients with DN [11]. We have previously
mRNA expression of p16 was significantly lower in diabetic shown an abnormal hyperplastic growth phenotype in
patients with DN. No hypermethylation of p16 gene was de- cultured skin fibroblasts from type 1 diabetic patientstected, and no abnormal migrating bands were noticed on
with DN as compared to type 1 diabetic patients withoutSSCP-PCR analysis in cells from patients with DN.
DN and normal control subjects [12]. However, the un-Conclusion. Our data indicate that cells from patients with
DN exhibit significantly lower protein and mRNA expression derlying molecular basis for this abnormal growth phe-
of p16. This study could have not only important implications notype is unknown.
for the understanding of the pathogenesis of DN, but also the Increasing evidence indicate that mammalian cell pro-absence of p16 may ultimately serve as an early marker for DN.
liferation is ultimately regulated by the sequential activa-
tion and inactivation of a family of serine/threonine pro-
tein kinases known as cyclin-dependent kinases (CDK)Diabetic nephropathy (DN) remains the single most
[13–15]. Two families of CDK inhibitors block the ac-common cause of renal failure in the United States [1, 2].
tivity of the cyclin-CDK complexes [13–15]. The INK4The onset of proteinuria in diabetic patients is not only
family of CDK inhibitors (p16INK4a, p15INK4b, p18INK4c, and
p19INK4d) specifically block the G1-type cyclin D/CDK4-6
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consists of two overlapping genes, each regulated by itsReceived for publication September 13, 2002
own promoter, which through alternative reading framesand in revised form December 4, 2002
Accepted for publication January 27, 2003 encode for two unrelated proteins, p16 and p19ARF [16–21].
In contrast to p16, p19ARF is not a CDK inhibitor but 2003 by the International Society of Nephrology
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Table 1. Clinical features of type 1 diabetic patients with and without nephropathy, nondiabetic patients with nephropathy,
and control subjects
Diabetic patients
Nondiabetics
With nephropathy Without nephropathy with nephropathy Control subjects P value
Number M/F 8 (5/3) 8 (4/4) 6 (2/4) 8 (4/4) —
Age yearsSE 383 363 413 322 0.165
Age range years 21–52 27–48 36–51 22–41 —
Duration of diabetes yearsSE 273 253 — 0.6814
Duration range years 17–47 14–37 — —
Hemoglobin A1C %SE 10.10.4 7.80.2 5.60.5 0.001
Mean arterial blood pressure mm HgSE 1046 903 996 0.153
Albumin excretion rate mg/24 hoursSE 2122522 72 50171367 0.001
Albumin excretion range mg/24 hours 742–5000 3–19 2800–11700 —
Creatinine clearance mL/minSE 618 1236 11217 0.001
Creatinine clearance range mL/min 40–97 105–155 57–126 —
Data are shown as mean  SE. Statistical significance is based on one-way analysis of variance (ANOVA) among different groups.
is involved in cell cycle regulation via the MDM2/p53 gave written informed consent. Type 1 diabetic patients
pathway [16]. The p16 protein binds to CDK4-6 and were recruited from the Northwestern Medical Faculty
inhibits the activity of cyclin D/ CDK4-6 complexes [21]. Foundation Diabetes Clinic. Type 1 diabetes was defined
Despite the widespread of alterations of p16 in senes- by the American Diabetes Association (ADA) criteria
cence, immortalization, and tumorgenesis, little is known [39]. Two groups of type 1 diabetic patients, a group of
about the transcriptional regulatory mechanism of this age-matched normal controls subjects (eight patients in
gene. It was initially thought that p16 protein levels peak each group), and a group of nondiabetic nephropathic
at the G1/S transition [22]. However, further studies show patients (six patients) were studied (Table 1). Diabetic
that once p16 gene expression is activated, it does not patients were categorized on the basis of their urinary
fluctuate significantly during the cell cycle [23]. It is albumin excretion rates (AER) to either normoalbumi-
known that the expression of p16 protein increases with nuric, or overt nephropathic patients. Type 1 diabetic
age [24, 25], and interestingly, p16 protein expression is patients excreting more than 300 mg/24-hour urine were
increased by the accumulation of cell doublings in culture classified as having overt nephropathy. Those patients ex-
[24, 25]. It is also well established that p16 is transcrip- creting less than 30 mg/24-hour urine were classified as
tionally regulated [24]. Recent experimental data indi- normoalbuminuric. Only normoalbuminuric patients with
cate that p16 may be inactivated by hypermethylation 12 or more years after the diagnosis of diabetes were
of its promoter region [26–30]. The p16 gene contains a included in this study. All diabetic patients with nephrop-
5CpG island in the promoter and first exon, and methyl- athy except for one patient were taking antihypertensive
ation of the cytosine base in this region has been shown medications, including angiotensin-converting enzyme
to provide an important mechanism for inactivation and (ACE) inhibitors. Nondiabetic nephropathic patients
silencing of p16 gene expression [26–32]. In addition to
were recruited from the Northwestern Medical Facultyhypermethylattion, another known mechanism of p16
Foundation Renal Clinic after obtaining informed con-protein regulation is gene polymorphism. More than 150
sent. Four of the nondiabetic patients with nephropathysequence variations in the coding exons of p16 relative
had membranous glomerulonephritis, and two were di-to the wild-type sequence have been reported [33–38].
agnosed with focal segmental glomerulosclerosis. All ofA database of p16 mutations and polymorphism identi-
the nondiabetic patients with nephropathy were takingfies at least 10 polymorphism in the coding region and
ACE inhibitors.3-untranslated region (UTR) of p16 [38].
The current study was undertaken to examine the cor- Procedures
relation between the expression of p16 protein and the
Urinary albumin excretion was measured using a spe-presence of DN in dermal fibroblasts from type 1 diabetic
cific fluorometric immunoassay in urine samples col-patients. In addition, we analyzed genetic and epigenetic
lected over 24 hours and expressed as mg/24 hours. Glo-regulation of p16 gene in cells obtained from type 1
merular filtration rate was estimated from a 24-hourdiabetic patients with DN.
measurement of the clearance of endogenous creatinine.
Arterial blood pressure was measured, with a standard
METHODS mercury sphygmomanometer to the nearest 2 mm Hg,
Patients in each patient after at least 10 minutes of rest in the
supine position. Mean arterial blood pressure was calcu-All procedures were approved by the Institutional Re-
view Board at Northwestern University, and each patient lated as the diastolic blood pressure plus one third of
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the pulse pressure at the time of the skin biopsies. Skin by using one set of primers to amplify both the target p16
fibroblasts were obtained using a standard 4 mm skin cDNA and the competitor DNA. Total RNA was extracted
punch biopsy, as previously reported by us [40]. Briefly, from cells using the Total RNA Isolation System (In-
biopsies were taken from the costovertebral angle of the vitrogen, Carlsbad, CA, USA), as described by the manu-
back at an anesthetized site. Cells were dispersed with a facturer. A previously prepared construct “minigene con-
forceps and grown in culture. Cells were fed twice weekly struct” was used as the template (Genbank accession No.
with Dulbecco’s modified Eagle’s medium (DMEM-F12) U17140). This minigene construct contains the primer
(Gibco, Grand Island, NY, USA), supplemented with sequences for -actin with an expected size of 224 bp.
10% fetal calf serum (FCS) (U.S. Biotechnologies, Par- Using this construct as the template, a competitive RT-
kerford, PA, USA), penicillin (100 U/mL), streptomycin PCR product was constructed with the following primers:
(100 g/mL), and fungizone (250 g/mL) at 37C in a 5-CAACGCACCGAATAGTTACGGACGACATG
humidified atmosphere with 5% CO2. GAGAAGATCT GG-3 (forward) and 5-GACACGC
TGGTGGTGCTGATGCGGCAGTGGCC AT-3 (re-Western blot analysis
verse). The underlined portions of the above primers are
Early passaged (6 to 9 passages) skin fibroblasts were the p16 target gene primer sequences, the remaining se-
made quiescent by serum deprivation for 48 hours. For
quences were -actin primer sequences designed to yield
each experiment, a total of 5  105 cells were seeded
a competitive product of approximately 261 bp. This prod-in 150 mm2 dishes, and at subconfluence (70% to 75%
uct was then cloned into a plasmid vector pCRII usingconfluence), fibroblasts were made quiescent by incuba-
the TA Cloning Kit Dual Promoter (Invitrogen) as in-tion in DMEM media for 48 hours as previously de-
structed by the manufacturer. Subsequently, the ligationscribed [40]. Cells were washed with phosphate-buffered
reaction product was transformed into TOP10F compe-saline complete (PBS), scraped off the bottom of the
tent cells (Invitrogen). After isolation of plasmid DNAdish in 1 mL PBS, and microcentrifuged at 15C. The
using the Concert Rapid Plasmid Miniprep System (In-supernatant was aspirated and the pellet was resus-
vitrogen), the plasmid DNA was digested using EcoR1pended in 500 mL lysis buffer [50 mmol/L Tris-HCL
and the insert sequence was confirmed at the Northwest-(pH 7.4), 150 mmol/L NaCl, 25 mmol/L ethylenediamine-
ern University Biotechnology facility. For RT, after iso-tetraacetic acid (EDTA), 5 mmol/L ethyleneglycol tetra-
lation of total RNA, first-strand cDNA synthesis wasacetate (EGTA), 0.25% Na-deoxycholate, 1% Nonidet
performed using the SuperScript II Reverse Transcript-P40 (NP-40), 1 mmol/L dithiothreitol (DTT), 1 mmol/L
Na metavanadate (VO3), 1 mmol/L NaF, 0.1 mg/mL ase (Invitrogen) in 20 L of the total volume. The reac-
phenylmethylsulfonyl fluoride (PMSF), 2 mg/mL leupep- tion mixtures contained 50 mmol/L Tris-HCL (pH 8.3),
tin, 0.234 TIU/mL aprotinin, and 1 mg/mL pepstatin A]. 75 mmol/L KCL, 3 mmol/L MgCl2, 10 mmol/L DTT,
The cells were lysed by repeated passage through a 27 and 500 mmol/L each of deoxyadenosine triphosphate
gauge needle and centrifuged at 4000g for 15 minutes at (dATP), 32P deoxycytidine triphosphate (dCTP), deoxy-
4C to pellet debris, and the supernatant was collected. guanosine triphosphate (dGTP), and deoxythymidine tri-
Following measurement of the protein concentration, phosphate (dTTP). After incubation at 42C for 2 minutes,
100g of total cellular lysate was mixed with 2 electro- 50 U of the SuperScript II RT and 10 U of RNase inhibitor
phoresis sample buffer (62.5 mmol/L Tris-HCL, pH 6.7, were added and the mixture was incubated for another
20% glycerol, 2% sodium dodecyl sulfate (SDS), 5%  50 minutes at 42C. The reaction was terminated at 70C
mercaptoethanol, and 0.02% bromophenol blue), and for 15 minutes. Each set of amplification was carried out
boiled for 4 minutes. Samples were resolved in 12% in 25 L total volume containing serial dilutions of com-
SDS-polyacrylamide gel electrophoresis (PAGE), and the
petitor, 1L of cDNA, 10 pmol of each primer specific
protein was then immunoblotted and probed with a mono-
for the p16 or -actin as previously mentioned, 10 mmol/Lclonal anti-p16 antibody (Santa Cruz Biotechnology, Santa
of each desoxynucleoside triphosphate (dNTP), 1 U ofCruz, CA, USA), at a dilution of 1:500 overnight and
Taq polymerase in the standard PCR buffer with 32 cyclesthen visualized using the ECL chemiluminescence sys-
of 1 minute at 94C for denaturing, 30 seconds at 58Ctem (Amersham Life Science, Piscataway, NJ, USA).
for annealing, and 1 minute at 72C for extension, followed
by a final extension for 10 minutes at 72C. For p16, theCompetitive reverse transcription-polymerase
chain reaction two PCR products, wild-type (176 bp) and the MIMIC
competitor (261 bp) were resolved on 2.0% agarose gelsTo analyze p16 gene expression in skin fibroblasts from
stained with ethidium bromide. For -actin, the two PCRdiabetic patients with DN as compared to cells from dia-
products, wild-type (461 bp) and the MIMIC competitorbetic patients without DN and in control subjects, com-
(224 bp) were resolved on 1.2% agarose gels stainedpetitive reverse transcription-polymerase chain reaction
(RT-PCR) was used to quantify p16 mRNA expression with ethidium bromide.
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Table 2. Oligonucleotide primers used for MS-PCR and polymerase complete methylation of the p16 promoter was used as
chain reaction-single-stranded conformational polymorphism
a positive control.(PCR-SSCP) analysis
Gene/exon Primer pairs (sense/antisense) Size (bp) Single-stranded conformational polymorphism (SSCP)
p16-M ttattagagggtggggcggatcgc 150 PCR was carried out under standard conditions con-
gaccccgaccgcgaccgtaa
taining 100 ng of genomic DNA template, 2 L 10 p16-U ttattagagggtggggtggattgt 151
caaccccaaaccacaaccataa PCR buffer [1  10 mmol/L Tris (pH 8.3), 50 mmol/L
p16-exon 1 tctgcggagagggggagagcaggca 279 KCl, 1.5 mmol/L MgCl2, and 0.01% gelatin], 3.2 L ofgcgctacctgattccaattc
dNTPs (1.25 mmol/L each of dATP, dCTP, dGTP, andp16-exon 2a acaagcttcctttccgtcatgccg 244
ccaggcatcgcgcacgtcca dTTP), 0.4 L forward primer (20 mol/L), 0.5 L of
p16-exon 2b ttcctggacacgctggtggt 240 reverse primer (20 mol/L), 0.5 L labeling reaction,
tctgagctttggaagctctcag
0.1 L Amplitaq DNA polymerase (5 U/L), and 8.3 Lp16-exon 3 gcctgttttctttctgccctctg 144
cgaaagcggggtgggttgt dimethyl sulfoxide (DMSO) (12%). Specific set of prim-
ers for exon 1, exon 2-a, 2-b, and exon 3 are shown inPrimers are shown as paired sense (top) and antisense (bottom). Abbreviations
are: P16-M, p16 methylated; p16-U, p16 unmethylated. Table 2. For amplification, each sample was denatured
at 94C for 5 minutes and subjected to 35 amplification
cycles. Each cycle consisted of 30 seconds denaturing at
95C, 30 seconds annealing at 65C (for exon 3, 30 sec-Methylation-specific polymerase chain reaction
onds at 57C), and 30 seconds extension at 72C, followed
The CpGWIZ p16 Methylation Assay Kit was used by 4 minutes final extension at 72C. Subsequently, 8 L
according to manufacturer’s description (Oncor, Inc., of PCR products were denatured in 30 L of denatur-
Gaithersberg, MD, USA). This assay is based on the prin- ing loading dye [98% formamide, 10 mmol/L NaOH,
ciples of methylation-specific PCR (MSP) described by 20 mmol/L EDTA, 0.05% (wt/vol) bromphenol blue and
Herman et al [41]. Briefly, DNA was modified by bisul- 0.05% (wt/vol) xylene cyanol] at 98 for 5 minutes. The
fate reaction and then underwent two separate PCR samples were loaded on an 8% polyacrylamide gel and
reactions using unmethylated-specific and methylated- run at 1.25 vol/cm in 1 Tris-borate-EDTA (TBE) in
specific amplifiers. The bisulfate treatment converts the 4C for approximately 18 to 24 hours. After electropho-
unmethylated cytosine to uracil, while 5-methylcytosines resis, the gels were fixed and stained with silver. The
remain unaltered. Thus, the sequence of treated DNA staining was subsequently stopped by immersing the gel
will differ if the DNA is originally methylated versus un- in 5% acetic acid. Concurrently, following amplification
methylated. For bisulfate treatment, 1 g of DNA was of PCR products, the DNA products were sent for direct
denatured by NaOH for 10 minutes at 37C. Thirty mi- sequencing analysis at the Northwestern Sequencing Fa-
croliters of 10 mmol/L hydroquinone and 520 L of cility.
3 mol/L sodium bisulfite were then added and mixed, and
Statistical analysissamples were incubated at 50C for 16 hours. Modified
DNAs were purified and eluted into 50 L of water. Mod- Analysis of variance (ANOVA) was used to compare
ification was completed by NaOH treatment (0.3 mol/L the differences among different groups. The unpaired t
final concentration) for 5 minutes at room temperature, test was used to test the differences between diabetic
followed by ethanol precipitation. Bisulfite-modified patients with and without nephropathy. P values 	0.05
DNA was used as a template for MSP using primers were considered significant.
specific for either the methylated or the modified un-
methylated sequences as described previously by Her-
RESULTSman et al (Table 2) [41]. For PCR reactions, a volume
Patient characteristicsof 25 L PCR mixture containing 100 ng DNA, dNTPs
at 250mol/L each, 1.5 mmol/L MgCl2, 1mol/L primer, In patients with DN, the creatinine clearance was mod-
1  reaction buffer and 1 U of Taq polymerase (Roche erately reduced as compared to diabetics without DN
Diagnostics, Indianapolis, IN, USA) was used for ampli- and nondiabetic patients with nephropathy (Table 1). By
fication. Reactions were performed in a 2400 Perkin- design, the mean urinary AER was significantly higher in
Elmer thermal cycle for 35 cycles (45 seconds at 95C, patients with DN and nondiabetic patients with nephrop-
45 seconds at the annealing temperature of 60C for athy as compared to diabetics without DN. Duration of
methylated, 65C for unmethylated PCR reaction, and diabetes and age were not significantly different between
60 seconds at 72C) followed by a 7-minute extension at diabetics with and without DN. All patients with overt
72C. The 10 L of PCR product was loaded onto 1.2% DN were hypertensive and were taking antihypertensive
agarose gel and visualized by ethidium-bromide staining. medications that included ACE inhibitors except for one
patient who was not on ACE inhibitor. Glycemic controlA colon cancer-derived cell line (SW620) with known
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p16 mRNA expression
To examine the mRNA expression of p16 in cells from
patients with DN and to confirm transcriptional regula-
tion of p16 protein in cultured skin fibroblasts, mRNA
from cells obtained from patients with and without DN
in addition to control subjects were processed for com-
petitive RT-PCR. A linearity in the ratios of PCR prod-
ucts of p16 cDNA in relation to plasmid DNA could
be maintained when plotted against 10
1 to 10
7 serial
logarithmic dilutions of the competitive plasmid DNA.
Within this range of serial dilutions, the bands of p16
gene and plasmid DNA products were discernible for
densitometric analysis to obtain a ratio. In cells from
patients with DN, a ratio of one was noted at 10
5 dilu-
tions of the competitive DNA, while in cells from dia-
betic patients without DN, a ratio of one was obtained
at 10
4 dilutions, suggesting a significant down-regulation
of p16 mRNA expression in cells from patients with DN.
A representative experiment is shown in Figure 2A. For
the -actin, a ratio of one was obtained at dilutions of
10
4 of the competitive plasmid DNA in all groups. There
was no change in the -actin mRNA expression in cells
from patients with and without DN. Figure 2B shows a
representative experiment. Figure 2C summarizes the
result of p16 mRNA expression using competitive RT-
PCR in seven diabetic patients without DN as compared
to seven patients with DN. These results are consistentFig. 1. p16INK4a protein expression. (A ) A representative experiment
of p16 protein expression in a control subject as compared to a diabetic with data on p16 protein expression and also confirmed
patient without diabetic nephropathy (DN), a nondiabetic patient with the altered transcription of p16 gene in cultured skinnephropathy, and a diabetic patient with DN. (B) Relative p16 protein
fibroblasts from type 1 diabetic patients with DN.expression in cultured skin fibroblasts from eight control subjects, eight
diabetic patients without DN, six nondiabetic patients with nephropa-
thy, and eight diabetic patients with DN. Values are the mean densito- Promoter methylation in the p16 gene
metric values  SE. *P  0.05.
The strikingly reduced levels of p16 protein and mRNA
detected in fibroblasts from patients with DN led us to
investigate the epigenetic mechanism of p16 gene down-as determined by hemoglobin (HbA1C) was poorer in pa- regulation by assessing the methylation status of the pro-tients with DN. Mean arterial blood pressure was not
moter region of the p16 gene using methylation sensitivesignificantly different among the groups. However, dia-
PCR. A colon cancer-derived cell line (SW620) with com-betic patients with DN had significantly higher mean arte-
plete methylation of the p16 promoter was used as a pos-rial blood pressure as compared to diabetics without DN.
itive control. Fibroblasts from control subjects were used
as controls for the unmethylated p16 promoter. As shownp16 protein expression
in Figure 3, no aberrant methylation was detected in theTo assess the differences in protein expression, p16
p16 gene in fibroblasts obtained from patients with DN.protein was measured using Western blot analysis from
two separate lysates. Figure 1A shows a representative
PCR-SSCP analysisexperiment. As shown in Figure 1A, p16 protein expres-
The human p16 gene structure comprises three exons,sion was undetectable or markedly lower in cells from
with exon 1 and 2 constituting almost 97% of the codingdiabetic patients with DN (4.0  1.3) as compared to
region of the gene [38]. Exon 1 is spliced to exons 2cells from diabetics without DN, nondiabetic patients
and 3 to form a transcript that encodes p16, whereaswith nephropathy, and from controls (25.3  4.8 and
exon 1 is spliced to the same exons 2 and 3 to form24.7  4.1, and 26.5  5.3, respectively, P  0.05).
another novel transcript that encodes p19ARF in an alter-Figure 1B summarizes the results of p16 protein expres-
native reading frame relative to p16. For mutation analy-sion indicating a significant difference in p16 protein
sis on exon 1, 2 and 3, we carried out PCR-SSCP analysisexpression among the four groups (P  0.05, one-way
ANOVA). using the primers in Table 2. Exons 1 and 3 were covered
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Fig. 3. Analysis of p16 promoter hypermethylation in cultured skin
fibroblasts from a type 1 diabetic patient with diabetic nephropathy
(DN). The polymerase chain reaction (PCR) products in lane U show
the presence of unmethylated templates of p16 gene, whereas the prod-
ucts in lane M indicate the presence of methylated templates. A colon
cancer-derived cell line (SW620) was used as positive control. Fibro-
blasts from control subjects were used as control for unmethylated p16
promoter. PCR for methylated p16INK4a sequences shows a band in the
SW620 cell line. In contrast, no amplification was observed in lane M
in a patient with DN.
Fig. 2. Expression of p16 mRNA by competitive reverse transcription-
polymerase chain reaction (RT-PCR). (A) A representative experiment
of p16 and the competing p16 MIMIC products in a patient without dia-
betic nephropathy (DN) (Diabetic) as compared to a diabetic patient
with DN (DN) using serial dilutions of the p16 MIMIC with a constant
amount of target cDNA. The sizes for p16 and p16 MIMIC products
were 176 and 261 bp, respectively. A significant decrease in the amplifi-
cation of the p16 cDNA was observed in dermal fibroblasts between a
diabetic patient without DN as compared to cells from a patient with Fig. 4. Polymerase chain reaction-single-stranded conformational poly-
DN when plotted against the log dilutions of the competitive p16 MIMIC morphism (PCR-SSCP) analysis of p16 exon 1 in cultured skin fibro-
cDNA. The arrows indicate that the ratio of one was shifted from 10
4 blasts from a control subject, a diabetic patient without diabetic
in cells from a diabetic patient to 10
5 in cells from a patient with DN. nephropathy (DN), and a patient with DN. No aberrant migration frag-
(B) For control, serial dilutions of -actin MIMIC were amplified with ments were noted in the sample from patient with DN. Concurrently,
fixed amount of -actin cDNA. The sizes for -actin and -actin MIMIC the DNA products were sent for direct sequence analysis of the bands
products were 461 and 224 bp, respectively. No significant differences shown. Direct sequencing did not show any evidence of mutations in
were observed in -actin cDNA vs. competitive -actin MIMIC cDNA cells from patients with DN.
in dermal cells from patients with and without DN. A ratio of one
was confined to the 10
4 log dilutions of the competitive cDNA. (C )
Expression of p16 mRNA was compared using 1  10
5 attomol/reac-
tion of p16 MIMIC cDNA in seven diabetic patients with and without
DN. Values are the mean densitometic values  SE. *P  0.05. a number of phenotypic abnormalities that include en-
hanced activity of the sodium-hydrogen antiporter [12, 42],
enhanced collagen synthesis [43], defective antioxidantwith single PCR products, and exon 2 was covered by two
activity [44], increased 3 integrin subunit expressionPCR products (Table 2). PCR-SSCP analysis revealed no
[45], and an increased [3H]-thymidine incorporation con-abnormal migrating bands in cells from patients with
sistent with a hyperplastic growth phenotype [12]. All ofDN as compared to cells from diabetic patients without
these abnormalities suggest an intrinsically altered cellDN and control subjects (Fig. 4). Using DNA sequence
response to the diabetic milieu in cells from patients withanalysis, we found no evidence of germ-line mutations
DN. In this study, we examined the correlation betweenwithin exons 1, 2, and 3.
p16 protein expression in cultured dermal fibroblasts and
the presence of DN. In addition, we analyzed genetic
DISCUSSION and epigenetic regulation of p16 gene in skin fibroblasts
from type 1 diabetic patients with DN.We and others have previously shown that dermal
fibroblasts from type 1 diabetic patients with DN exhibit The results of this study indicate that cultured skin
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fibroblasts from type 1 diabetic patients with DN have from the eukaryotic genome over evolution, except for
small (0.5 to several kb) stretches of DNA, known asa significantly lower protein expression of p16 as com-
pared to cells from diabetics without DN, nondiabetic “CpG islands” [28, 29]. These regions are usually “pro-
tected” from methylation, and this lack of methylationpatients with nephropathy and control subjects. The dif-
ference in p16 protein expression in this study is unlikely might be a prerequisite for active transcription, as aber-
rant methylation of CpG islands has been associatedto be due to methodologic differences. The site of the
biopsy was the same in all subjects, and in each experi- with transcriptional inactivation of regulatory regions of
imprinted genes. The p16 gene contains a 5CpG islandment, cells from diabetic patients with and without DN
and controls were studied in matched sets. All the experi- in the promoter and first exon, and methylation of the
cytosine base in this region has been shown to provide anments were conducted under identical experimental con-
ditions. The differences in protein expression of p16 pro- important mechanism for silencing p16 gene expression
[26–29, 32–38]. De novo methylation of the p16 gene hastein is also unlikely to be due to uremia itself, as the
mean glomerular filtration rate in the group of patients been implicated as the primary mechanism of inactiva-
tion of the gene in various cancer cell lines and in somewith DN was 61 mL/min. The effect of hyperglycemia
on p16 protein expression is still largely unknown and primary tumors [26–28, 33, 38]. Our data are consistent
with that of previous studies, indicating that p16 is largelythe modulatory effect of hyperglycemia on p16 protein
cannot be completely ruled out. Despite our best efforts, transcriptionally regulated. However, we could not de-
tect significant hypermethylation in the promoter regionthere was a significant difference in HbA1C between the
two diabetic groups (7.8  0.2 mg/dL in diabetics vs. of the p16 in cells from patients with DN, suggesting
that epigenetic regulation of p16INKa is not the underlying10.1  0.4 mg/dL in patients with DN). However, we
could not detect any significant differences in p16 protein mechanism of p16 down-regulation in cells from patients
with DN.expression among diabetic patients without DN and non-
diabetic patients with nephropathy, suggesting that a We also considered p16 polymorphism as a possible
mechanism of decreased p16 expression. The p16 genehigh glycemic milieu is not the only determinant of al-
tered expression of p16 protein in cells from patients carries several polymorphisms. The most extensively doc-
umented polymorphism of p16 gene, A148T, results fromwith DN.
The effect of antihypertensive therapy, especially ACE a GA change at nucleotide 442 which ablates a SacII
site. The other two common polymorphic sites (the 500inhibitors on p16 protein, is also unknown. Recently,
Wolf et al [46] showed that ACE inhibitors may modu- CG and 540 CT) are within the 3 UTR and the po-
tential influences of these polymorphism on the functionlate the protein expression of several CDK inhibitors, in-
cluding p16 and p27 in vivo. The authors concluded that or expression of p16 protein is not well established [47].
It is generally accepted that frameshift mutations withinthe use of enalapril may decrease the protein expression
of p16 in BBdp rats, an autoimmune model of type 1 exon 1 results in a truncated p16 protein causing loss of
function [38]. In this study, using PCR-SSCP method fordiabetes. In this study, the modulatory effect of ACE
inhibitors, especially if it persists after several passages the analysis of exons 1, 2, and 3 of the p16 gene, a uniform
band migration was detected suggesting that a p16 singlein vitro, on p16 protein should be considered. However,
p16 protein expression was not decreased in nondiabetic nucleotide polymorphism is not the underlying regula-
tory mechanism for the observed down-regulation ofpatients with nephropathy despite the use of ACE inhibi-
tors in all of those patients, suggesting that the use of p16 expression in cells from patients with DN. Further
studies are needed to unravel the regulatory mechanismsACE inhibitors is not the likely underlying mechanism
of low p16 protein expression. of p16 in the diabetic milieu. Currently, studies are being
conducted in our laboratory to shed light on the effectLittle is known about the underlying regulatory mech-
anisms of the p16 gene. It is well established that p16 is of p16 and other cell cycle regulatory proteins in the
hyperplastic growth phenotype in fibroblasts from pa-transcriptionally activated [38]. Several known mecha-
nisms of transcriptional down-regulation/inactivation of tients with DN. Our results indicate that CIP/KIP family
of CDK inhibitors are not altered in dermal fibroblaststhe p16 gene include hypermethylation, point mutations,
small deletions, and large homozygous deletions [38]. in patients with DN (unpublished data).
Currently, ACE inhibitors are instituted in the courseHowever, somatic mutations in the p16 gene are rare
except in hereditary melanomas [37]. The initial evidence of nephropathy in patients with type 1 diabetes when mi-
croalbuminuria is detected. However, the presence of mi-of epigenetic regulation of the p16 gene relied on South-
ern blotting with methylation-sensitive restriction en- croalbuminuria may no longer be considered as an early
predictor of DN, but rather an early manifestation ofzymes, particularly SacII and SmaI [26, 27, 37]. In the
normal mammalian genome, methylation occurs only at the disease [48]. The presence of microalbuminuria is the
best available noninvasive predictor of DN risk and shouldcytosine (C) 5 to guanosine (G). It seems that CpG di-
nucleotide-rich regions have been progressively depleted be regularly measured according to established guide-
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tured skin fibroblasts from patients with insulin dependent diabeteslines. However, some diabetic patients with microalbu-
mellitus with and without nephropathy and its association to over-
minuria have quite advanced renal structural changes, activity of the Na/H antiporter. Kidney Int 50:1684–1693, 1996
13. Sherr CJ, Roberts JM: Inhibition of mammalian G1 cyclin-depen-and the presence of microalbuminuria in these cases may
dent kinase activity. Genes Dev 9:1149–1163, 1996be a marker rather than a predictor of DN [48]. New
14. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79:551–555,
biochemical or genetic predictors are needed to define 1994
15. Sherr CJ, Kato J, Quelle DE, et al: D-type cyclins and theirpatients who are at risk of developing DN early in the
cyclin-dependent kinases: G1 phase integrators of the mitogeniccourse of diabetes. If our findings are confirmed, this
response. Cold Spring Harb Symp Quant Biol 59:9–11, 1994
may have important implications. First, it may further 16. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative read-
ing frames of the INK4a tumor suppressor gene encode two unre-our understanding of the pathogenesis of DN. Second,
lated proteins capable of inducing cell cycle arrest. Cell 83:993–the absence of p16 may ultimately serve as an early
1000, 1995
genetic predictor of DN, allowing effective interventions 17. Serrano M, Hannon GJ, Beach D: A new regulatory motif in
cell-cycle control causing specific inhibition of cyclin D/CDK4.such as intensive diabetes management and ACE inhibi-
Nature 366:704–707, 1993tor therapy, to be initiated very early in the course of
18. Coleman KG: Identification of cdk4 sequences involved in cyclin
diabetes with the resultant delay of progression or per- D1 and p16 binding. J Biol Chem 272:18869–18874, 1999
19. Guan KL, Jenkins CW, Li Y, et al: Isolation and characterizationhaps prevention of the nephropathy. Further prospective
of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.studies are needed to assess the use of p16 expression
Mol Biol Cell 7:57–70, 1996
in skin fibroblasts as a predictor of DN and establish the 20. Okuda T, Hirai H, Valentine VA, et al: Molecular cloning, expres-
sion pattern, and chromosomal localization of human CDKN2D/correlation between p16 expression and genetic suscepti-
INK4d, an inhibitor of cyclin D-dependent kinases. Genomics 29:bility to DN.
623–630, 1995
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